证券代码：301080 证券简称：百普赛斯 公告编号：2026-001 北京百普赛斯生物科技股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无变更、否决提案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开情况 1、现场会议召开时间：2026 年 1 月 6 日（星期二）下午 14:00 2、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的时间为 2026 年 1 月 6 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为 2026 年 1 月 6 日 9:15-15:00 期间的任意时间。 3、会议召开地点：北京市北京经济技术开发区宏达北路 8 号北京百普赛斯 生物科技股份有限公司（以下简称"公司"）二层会议室 4、会议的召开方式：现场表决与网络投票相结合的方式 5、会议召集人：公司董事会 6、会议主持人：经过半数董事推选，本次会议由董事苗景赟先生主持。 7、本次股东会的召集 ...

上海市通力律师事务所 关于北京百普赛斯生物科技股份有限公司 2026 年第一次临时股东会的法律意见书 致:北京百普赛斯生物科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受北京百普赛斯生物科技股份有限公司 (以下简称"公司")的委托,指派本所黄雅程律师、张幸律师(以下简称"本所律师")根据 《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规 和规范性文件(以下统称"法律法规")及《北京百普赛斯生物科技股份有限公司章程》(以 下简称"公司章程")的规定就公司 2026 年第一次临时股东会(以下简称"本次股东会") 相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东会有关的法律文件及其他文件、资料予以了核 查、验证。在进行核查验证过程中,公司己向本所保证,公司提供予本所之文件中的所有签 署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、完整和有效 的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东会召集和召开的程序、出席本次股东会人员资格 和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表 ...

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is experiencing growth in its business segments, particularly in cell immunotherapy and recombinant proteins, while benefiting from the depreciation of the RMB and being recognized as a "specialized and innovative" enterprise [2][3][4]. Group 1: Business Performance - The company reported a revenue of 613 million yuan for the period from January to September 2025, representing a year-on-year growth of 32.26% [9]. - The net profit attributable to the parent company for the same period was 132 million yuan, showing a year-on-year increase of 58.61% [9]. - The company's overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Product Development - The company has launched a specific antibody targeting the CD19 antigen in CAR-T cell therapy, enhancing detection methods and expanding its product offerings in cell and gene therapy [2]. - It has developed a range of high-quality recombinant proteins targeting various diseases and biomarkers, supporting the research and production of biopharmaceuticals [2]. - The company is actively developing products related to monkeypox virus, including recombinant proteins, antibodies, and test kits, to aid in vaccine and therapeutic drug development [2]. Group 3: Market Position and Recognition - The company has been recognized as a "national-level specialized and innovative small giant enterprise," which signifies its strong market position and innovation capabilities [3]. - It operates in the pharmaceutical and biotechnology sector, focusing on recombinant proteins and related technologies [8]. - The company has a diverse product revenue structure, with 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, and 3.04% from technical services [8].

Group 1 - The core viewpoint of the news is the performance and financial status of Beijing Baipusi Biotechnology Co., Ltd., which saw a stock price increase of 5.07% to 56.74 CNY per share, with a total market capitalization of 9.486 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with its main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] Group 2 - From the perspective of fund holdings, Guotai Fund has a significant position in Baipusi, with the Guotai Innovation Medical Mixed Fund A (018159) holding 21,600 shares, representing 5.2% of the fund's net value, making it the seventh-largest holding [2] - The Guotai Innovation Medical Mixed Fund A was established on April 18, 2023, with a latest scale of 17.7778 million CNY, and has achieved a year-to-date return of 38.09%, ranking 2210 out of 8155 in its category [2] Group 3 - The fund manager of Guotai Innovation Medical Mixed Fund A is Qiu Xiaoxu, who has been in the position for 3 years and 144 days, managing assets totaling 676 million CNY, with the best fund return during the tenure being 5.58% and the worst being 0.5% [3]

Investment Rating - The report maintains an "Outperform" rating for several companies in the pharmaceutical sector, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with promising pipelines and performance growth in the Biopharma/Biotech sector, maintaining an "Outperform" rating for Innovent Biologics, WuXi XDC Cayman, and others [5][23]. - It highlights the performance of the A-Shares pharmaceutical sector, which underperformed the market, with the SW Pharma & Bio index falling by 0.2% while the SHCOMP rose by 1.9% [7][18]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level of 66.7% as of December 26, 2025 [13][17]. Summary by Sections 1. Continued Recommendation for Innovative Drugs and Industry Chain - The report continues to recommend innovative drugs and the associated industry chain, highlighting the high demand and potential for revaluation in the pharmaceutical sector [5][23]. - Specific companies recommended include Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical, all rated as "Outperform" [5][6]. 2. A-Shares Pharmaceutical Sector Performance - In the fourth week of December 2025, the A-Shares pharmaceutical sector underperformed the broader market, with a decline of 0.2% compared to a 1.9% increase in the SHCOMP index [7][18]. - The best-performing sub-sectors included chemical raw materials (+2.0%) and medical equipment (+0.1%), while biological products saw a slight decline of -0.1% [9][18]. 3. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Biotechnology index down by 2.3% [18]. - In contrast, the U.S. pharmaceutical sector performed similarly to the market, with the S&P Healthcare Select Sector increasing by 1.0% [18].

Core Viewpoint - The biopharmaceutical sector experienced a slight decline of 0.02% on December 26, with Jindike leading the drop, while the Shanghai Composite Index rose by 0.1% and the Shenzhen Component Index increased by 0.54% [1] Group 1: Market Performance - The closing prices and performance of key biopharmaceutical stocks showed mixed results, with Heyi Biotech rising by 3.17% to 71.61 and Jindike falling by 2.54% to 21.88 [1][2] - The trading volume for Heyi Biotech was 33,900 shares, with a transaction value of 239 million yuan, while Jindike had a trading volume of 38,900 shares and a transaction value of 85.44 million yuan [1][2] Group 2: Capital Flow - The biopharmaceutical sector saw a net outflow of 185 million yuan from institutional investors, while retail investors had a net inflow of 142 million yuan [2] - Key stocks like Gann Li Pharmaceutical had a net inflow of 13.59 million yuan from institutional investors, but a net outflow of 24.81 million yuan from retail investors [3]

Group 1 - The biopharmaceutical sector increased by 0.18% on December 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] - Key stocks in the biopharmaceutical sector showed various performance, with Jindike (688670) rising by 4.66% to a closing price of 22.45 [1] Group 2 - The biopharmaceutical sector experienced a net outflow of 307 million yuan from institutional investors, while retail investors saw a net inflow of 359 million yuan [2] - Notable declines included Te Bao Biological (688278), which fell by 3.14% to a closing price of 80.90 [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Wan Ze Co. (000534) achieving a turnover of 488 million yuan [1][2] Group 3 - Jindike (688670) had a net inflow of 25.23 million yuan from institutional investors, while retail investors had a net outflow of 23.95 million yuan [3] - Other stocks like Zhi Xiang Jin Tai (688443) and Shen Zhou Cell (688520) also showed mixed net inflows and outflows from different investor categories [3] - The overall trend indicates a divergence in investor sentiment, with institutional investors pulling back while retail investors increased their positions [2][3]

Core Viewpoint - The company, Beijing Baipusi Biotechnology Co., Ltd., has shown significant growth in revenue and net profit, indicating a strong performance in the biotechnology sector, particularly in the recombinant protein market [2][3]. Group 1: Financial Performance - For the period from January to September 2025, the company achieved an operating income of 613 million yuan, representing a year-on-year growth of 32.26% [2]. - The net profit attributable to shareholders for the same period was 132 million yuan, reflecting a year-on-year increase of 58.61% [2]. - Cumulatively, the company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan distributed over the past three years [3]. Group 2: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 9.75% to 10,600, while the average number of circulating shares per person increased by 54.93% to 11,947 shares [2]. - The financing balance of the company was reported at 82.71 million yuan, which is 0.95% of the circulating market value, indicating a low level compared to the past year [1]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 13.56 million shares, an increase of 7.57 million shares from the previous period [3].

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The biopharmaceutical investment and financing environment has shown significant recovery since the second half of 2025, with a total financing amount of USD 30.32 billion from July to November 2025, representing a year-on-year increase of 30.90% [4] - The number of new drug IND applications stabilized in 2025, with approximately 1,897 applications from January to November, reflecting a year-on-year growth of about 7.91% [4] - The demand for CRO services has shown a clear turning point, and the report continues to recommend opportunities in the innovative drug industry chain (CXO + research services) for 2026 [4] Summary by Sections Industry Performance - The biopharmaceutical sector experienced a decline of 0.14% in the third week of December 2025, outperforming the CSI 300 index by 0.14 percentage points, ranking 22nd among 31 sub-industries [7][14] - The offline pharmacy sector saw the highest increase, rising by 5.59%, while the chemical preparation sector had the largest decline at 2.1% [18][22] Investment Opportunities - The report highlights the strong performance of leading CXO and research service companies, with many exceeding earnings expectations. Companies like WuXi AppTec and Tigermed have raised their earnings guidance for 2025 [5] - The report recommends a valuation switch opportunity for leading CXO and research service companies, given the continuous improvement in demand [5] Clinical Research Organizations (CRO) - There has been a notable improvement in orders for preclinical and clinical CROs, with expectations for significant improvements in financial statements for 2026 [6] - The report anticipates that the market demand will continue to focus on leading companies as the capacity of clinical CROs is expected to be streamlined [6] Monthly and Weekly Recommendations - The report recommends a monthly investment portfolio including companies such as Sanofi, Innovent Biologics, and others, focusing on innovative drug opportunities and valuation switch [8]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]